Novartis Wins Jury Verdict Over Zometa's Bone Death Risk

Law360, New York (May 15, 2013, 2:54 PM EDT) -- A New Jersey jury on Wednesday returned with a verdict for Novartis Pharmaceuticals Corp. in centralized litigation over its bone-strengthening drug Zometa, finding after a 13-day trial that the company did not fail to provide an adequate warning about dead jaw bone risks.

After fewer than six hours of deliberations starting Tuesday afternoon, the eight-member, all-male jury in Middlesex County Superior Court handed down its 7-1 decision in the case of Beverly Meng shortly after 11 a.m. Meng's lawsuit was the second to go on trial in the New Jersey mass tort, and Novartis has won both. The case was before...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS